Abivax has been granted a patent for a compound that can be used to treat and prevent RNA virus infections caused by viruses belonging to group IV or V of the Baltimore classification. The compound, represented by formula (I), can be administered to patients in need of treatment. GlobalData’s report on Abivax gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abivax, cancer treatment biomarkers was a key innovation area identified from patents. Abivax's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11739073B2) discloses a method for treating RNA virus infections caused by viruses belonging to group IV or V of the Baltimore classification. The method involves administering a therapeutically effective amount of a compound of formula (I) to a patient in need. The compound of formula (I) is further defined by various characteristics, including the presence of a divalent 5-membered heteroaromatic ring comprising 1, 2, 3, or 4 heteroatoms, which can be a triazole or an oxadiazole.
The patent claims also describe specific variations of the compound of formula (I), such as compounds of formula (Ia), (Ib), and (Id), as well as their pharmaceutically acceptable salts. These compounds can be used in the treatment of RNA virus infections caused by viruses belonging to group IV or V of the Baltimore classification, including RSV, Chikungunya, Influenza, and Dengue viral infections.
Additionally, the patent includes claims related to the synthesis process for manufacturing the compounds of formula (Ia), (Ib), and (Id). The synthesis process involves at least one step of coupling a compound of formula (II).
Furthermore, the patent covers pharmaceutical compositions comprising the compounds of formula (Ia), (Ib), or (Id) along with pharmaceutically acceptable excipients. The compositions can be used for the treatment of RNA virus infections caused by group IV or V viruses.
Overall, this granted patent provides a method for treating RNA virus infections caused by specific viruses and discloses compounds, their variations, synthesis processes, and pharmaceutical compositions for effective treatment. The patent's claims offer valuable insights into potential therapeutic options for combating RNA virus infections, which can have significant implications in the field of antiviral research and drug development.
To know more about GlobalData’s detailed insights on Abivax, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
